Artelo Biosciences Inc. has announced that it received a notice from The Nasdaq Stock Market LLC on May 22, 2025, indicating non-compliance with Nasdaq Listing Rule 5550(b)(1). This rule requires companies listed on The Nasdaq Capital Market to maintain a minimum stockholders' equity of $2,500,000. As of March 31, 2025, Artelo Biosciences reported stockholders' equity of $652,000, falling short of this requirement. Despite this, the company's stock will continue to be listed and traded on Nasdaq, provided other listing requirements are met. Artelo Biosciences has until July 7, 2025, to submit a compliance plan, potentially extending to November 18, 2025, to regain compliance. The company is assessing options to resolve the issue but there is no guarantee of success.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.